Didier Haguenauer is a Medical Doctor graduated from the University Paris Descartes France with Business Administration degree from ESSEC Business School (ESSEC Alumni). He joined Glycostem in 2018 as Senior Vice President Clinical and is Chief Medical Officer. He has been involved in Oncology Clinical Research and Medical Affairs for more than 25 years and in Cell therapy since 2016. Haguenauer has participated in the development of various oncology projects conducted by oncology market leaders such as AstraZeneca, or more recently biotech companies in immune-oncology such as Kiadis.
Dr. Didier Haguenauer MD, ESSEC
Chief Medical Officer